Pilot Study Evaluating Preference for 3‐mg Versus 6‐mg Subcutaneous Sumatriptan
- 5 April 2005
- journal article
- research article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 45 (4), 346-349
- https://doi.org/10.1111/j.1526-4610.2005.05072.x
Abstract
Subcutaneous sumatriptan (6 mg) is undeniably an excellent treatment of migraine. However, some patients have avoided using 6 mg sumatriptan because of unpleasant or unwanted side effects. To evaluate the efficacy of subcutaneous sumatriptan (3 mg) during a moderate or severe migraine attack. Thirty subcutaneous sumatriptan-naive patients with a history of migraine with and without aura treated their next two moderate or severe migraines with either 3-mg or 6-mg sumatriptan injection. The primary endpoint was whether patients preferred the low-dose (3 mg) or the high-dose (6 mg) subcutaneous sumatriptan. Other objectives included percentage of patients pain free at 15 and 30 minutes, 1 and 2 hours; a pain-free response lasting between 2 and 24 hours, patient satisfaction, and acceptability of formulation. A new combination endpoint (efficacy and lack of significant side effects) was also evaluated. Eighty percent of patients preferred 3-mg over 6-mg subcutaneous sumatriptan. At 1 hour postdose 57% of patients were pain free with 3 mg and 53% with 6 mg. At 2 hours postdose 87% were pain free with 3 mg and 80% with 6 mg. A sustained pain-free response was obtained by 70 to 80% of patients. When combining a pain-free response at 2 hours and a sustained pain-free response at 24 hours with no significant side effects, more patients met the endpoint with 3 mg (63 to 67%) than with 6 mg (33 to 50%). Combining efficacy and tolerability endpoints may be clinically meaningful and reflective of real-world expectations. In some patients, a lower dose of sumatriptan injection may be beneficial.Keywords
This publication has 8 references indexed in Scilit:
- The International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia, 2013
- Migraine — Current Understanding and TreatmentThe New England Journal of Medicine, 2002
- Acute Migraine Therapy: Do Doctors Understand What Patients With Migraine Want From Therapy?Headache: The Journal of Head and Face Pain, 1999
- Chest Symptoms after SumatriptanCephalalgia, 1996
- Sumatriptan in clinical practiceNeurology, 1996
- Treatment of Migraine Attacks with Subcutaneous Sumatriptan: First Placebo-Controlled StudyCephalalgia, 1992
- Treatment of Migraine Attacks with SumatriptanThe New England Journal of Medicine, 1991
- The Clinical Pharmacology, Pharmacokinetics and Metabolism of SumatriptanEuropean Neurology, 1991